Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $35000.0.

  • 10x Genomics' Gains from Investment Securities fell 9550.13% to $35000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $11.4 million, marking a year-over-year increase of 10203.86%. This contributed to the annual value of $11.4 million for FY2025, which is 10203.86% up from last year.
  • As of Q4 2025, 10x Genomics' Gains from Investment Securities stood at $35000.0, which was down 9550.13% from $3.1 million recorded in Q3 2025.
  • In the past 5 years, 10x Genomics' Gains from Investment Securities ranged from a high of $16.6 million in Q1 2022 and a low of -$652000.0 during Q4 2023
  • Moreover, its 5-year median value for Gains from Investment Securities was $1.4 million (2021), whereas its average is $3.8 million.
  • In the last 5 years, 10x Genomics' Gains from Investment Securities tumbled by 9941.79% in 2021 and then surged by 91913.36% in 2024.
  • Over the past 5 years, 10x Genomics' Gains from Investment Securities (Quarter) stood at $1.7 million in 2021, then skyrocketed by 864.03% to $16.6 million in 2022, then crashed by 103.94% to -$652000.0 in 2023, then soared by 219.33% to $778000.0 in 2024, then crashed by 95.5% to $35000.0 in 2025.
  • Its Gains from Investment Securities stands at $35000.0 for Q4 2025, versus $3.1 million for Q3 2025 and $7.8 million for Q2 2025.